Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Feb 15;7(5):FSO684.
doi: 10.2144/fsoa-2020-0190.

Implications of neuroendocrine tumor and diabetes mellitus on patient outcomes and care: a matched case-control study

Yael N Kusne  1 , Heidi E Kosiorek  2 , Matthew R Buras  2 , Patricia M Verona  3 , Kyle E Coppola  4 , Kelley A Rone  5 , Curtiss B Cook  6 , Nina J Karlin  4   5
Affiliations

Implications of neuroendocrine tumor and diabetes mellitus on patient outcomes and care: a matched case-control study

Yael N Kusne et al. Future Sci OA. .

Abstract

Aim: We aimed to determine the impact of diabetes mellitus (DM) on survival of patients with neuroendocrine tumors (NETs) and of NETs on glycemic control.

Patients & methods: Patients with newly diagnosed NETs with/without DM were matched 1:1 by age, sex and diagnosis year (2005-2017), and survival compared (Kaplan-Meier and Cox proportional hazards). Mixed models compared hemoglobin A1c (HbA1c) and glucose during the year after cancer diagnosis.

Results: Three-year overall survival was 72% (95% CI: 60-86%) for DM patients versus 80% (95% CI: 70-92%) for non-DM patients (p = 0.82). Hazard ratio was 1.33 (95% CI: 0.56-3.16; p = 0.51); mean DM HbA1c, 7.3%.

Conclusion: DM did not adversely affect survival of patients with NET. NET and its treatment did not affect glycemic control.

Keywords: cancer; endocrinology; prognostics.

PubMed Disclaimer

Conflict of interest statement

Financial & competing interests disclosure The authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties. No writing assistance was utilized in the production of this manuscript.

Figures

Figure 1.
Figure 1.. Mean HbA1c level during the year after cancer diagnosis for patients with diabetes mellitus.
The mean HbA1c level did not change significantly during the course of cancer treatment. HbA1c indicates hemoglobin A1c.
Figure 2.
Figure 2.. Mean (SD) glucose level for patients with and without diabetes mellitus.
No significant changes occurred in glycemic control in either group over 12 months (p = 0.34, interaction effect; p = 0.58, time effect). *Main effects and interactions.
Figure 3.
Figure 3.. Overall survival for patients with and without diabetes mellitus (K–M method).
DM: Diabetes mellitus; HR: Hazard ratio; K–M: Kaplan–Meier; NE: Not evaluable.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Appetecchia M, Lauretta R, Rota F. Sporadic gastroenteropancreatic neuroendocrine tumors. : Abdominal Neuroendocrine Tumors: Updates in Surgery. Carlini M ().Springer, Springer Milan Imprint, Milano, Italy, 53–62 (2018).
    1. Lakhani VT, You YN, Wells SA. The multiple endocrine neoplasia syndromes. Annu. Rev. Med. 58, 253–265 (2007). - PubMed
    1. Dasari A, Shen C, Halperin D et al. Trends in the incidence, prevalence, and survival outcomes in patients with neuroendocrine tumors in the United States. JAMA Oncol. 3(10), 1335–1342 (2017). - PMC - PubMed

    2. •• Reviews the epidemiology and therapeutic advances for patients with neuroendocrine tumors (NETs).

    1. Pape UF, Berndt U, Muller-Nordhorn J et al. Prognostic factors of long-term outcome in gastroenteropancreatic neuroendocrine tumours. Endocr. Relat. Cancer 15(4), 1083–1097 (2008). - PubMed
    1. Maggard MA, O'Connell JB, Ko CY. Updated population-based review of carcinoid tumors. Ann. Surg. 240(1), 117–122 (2004). - PMC - PubMed

LinkOut - more resources